News

Placing and Proposed Admission to Trading on AIM

Chepstow, South Wales, 6 December 2016 – Creo Medical Group plc (AIM: CREO) (“Creo” or the “Company”), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce that it has today published an admission document (the “Admission Document”) in relation to the proposed admission of the entire issued share capital of the Company to trading on the AIM Market of the London Stock Exchange, which is expected to take place on 9 December 2016 (“Admission”).    

Read More

First-in-Human Study

Clinical Study Demonstrates Safety and Efficacy of Microwave Coagulation of Blood Vessels During Advanced Colonoscopic Polypectomy

Read More

Digestive Disease Week (DDW) 2016, San Diego

DDW 2016 was a resounding success, including multiple meetings with our ever-growing network of international opinion leaders in the field of Therapeutic Endoscopy, advancing our collaboration in the development of our technology, techniques and training programs.

Read More

Peer reviewed publication demonstrating safety and efficacy of Speedboat RS2

A novel multimodality endoscopic device for colonic submucosal dissection using a combination of bipolar radiofrequency and microwave modalities   Zacharias P. Tsiamoulos from St. Mark’s Hospital London et al. published in Endoscopy.

Read More

Creo Medical closes $8.45m in new financing round

Creo Medical, an emerging leader in electrosurgery, today announced the completion of its latest financing round totalling $8.45m, including new investor Pentax Medical (HOYA Group). Participants in this financing round also include existing investors Finance Wales, the Angel CoFund and individual angel investors. To date, Creo Medical has secured investment totalling $20.7m.

Read More